Zydus Lifesciences Limited (BOM:532321)

Market Cap	887.50B
Revenue (ttm)	244.94B
Net Income (ttm)	49.20B
Shares Out	n/a
EPS (ttm)	48.89
PE Ratio	18.04
Forward PE	20.30
Dividend	11.00 (1.26%)
Ex-Dividend Date	Jul 25, 2025

Volume	25,225
Average Volume	20,847
Open	865.55
Previous Close	872.95
Day's Range	865.55 - 883.25
52-Week Range	797.05 - 1,059.00
Beta	n/a
RSI	41.01
Earnings Date	Feb 14, 2026

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 27,917
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.